{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T09:48:49Z","timestamp":1780566529830,"version":"3.54.1"},"reference-count":35,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T00:00:00Z","timestamp":1764115200000},"content-version":"am","delay-in-days":360,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000048","name":"American Cancer Society","doi-asserted-by":"publisher","award":["RSG-22-105-01-CSCT"],"award-info":[{"award-number":["RSG-22-105-01-CSCT"]}],"id":[{"id":"10.13039\/100000048","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","clinical-genitourinary-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Genitourinary Cancer"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.clgc.2024.102217","type":"journal-article","created":{"date-parts":[[2024,9,3]],"date-time":"2024-09-03T16:48:03Z","timestamp":1725382083000},"page":"102217","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Long-term Clinical Outcomes of Patients With Negative Pathology (pN0) at Primary Retroperitoneal Lymph Node Dissection"],"prefix":"10.1016","volume":"22","author":[{"given":"Fady","family":"Baky","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Liso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brandon","family":"Williams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0741-2150","authenticated-orcid":false,"given":"Andrea","family":"Knezevic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel A.","family":"Funt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2424-4635","authenticated-orcid":false,"given":"Darren R.","family":"Feldman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brett","family":"Carver","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joel","family":"Sheinfeld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0757-0885","authenticated-orcid":false,"given":"Richard S.","family":"Matulewicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clgc.2024.102217_bib0001","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.6004\/jnccn.2019.0058","article-title":"Testicular Cancer, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology","volume":"17","author":"Gilligan","year":"2019","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.clgc.2024.102217_bib0002","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1097\/JU.0000000000000318","article-title":"Diagnosis and treatment of early stage testicular cancer: AUA guideline","volume":"202","author":"Stephenson","year":"2019","journal-title":"J Urol"},{"key":"10.1016\/j.clgc.2024.102217_bib0003","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1200\/JCO.2014.56.2116","article-title":"Patterns of relapse in patients with clinical stage I testicular cancer managed with active surveillance","volume":"33","author":"Kollmannsberger","year":"2015","journal-title":"J Clin Oncol"},{"issue":"6_suppl","key":"10.1016\/j.clgc.2024.102217_bib0004","article-title":"European Association of Urology (EAU) testicular cancer guidelines panel: a new prognostic factor risk group classification for patients with clinical stage 1 seminoma in active surveillance","volume":"41","author":"Joost Boormans","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clgc.2024.102217_bib0005","doi-asserted-by":"crossref","first-page":"3817","DOI":"10.1200\/JCO.2013.53.5831","article-title":"Surveillance for stage I nonseminoma testicular cancer: outcomes and long-term follow-up in a population-based cohort","volume":"32","author":"Daugaard","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clgc.2024.102217_bib0006","doi-asserted-by":"crossref","first-page":"3762","DOI":"10.1200\/JCO.22.00118","article-title":"Primary retroperitoneal lymph node dissection for patients with pathologic stage II nonseminomatous germ cell tumor-N1, N2, and N3 disease: is adjuvant chemotherapy necessary?","volume":"40","author":"Tachibana","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.clgc.2024.102217_bib0007","doi-asserted-by":"crossref","first-page":"2781","DOI":"10.1200\/JCO.2005.07.132","article-title":"Retroperitoneal lymph node dissection for nonseminomatous germ cell testicular cancer: impact of patient selection factors on outcome","volume":"23","author":"Stephenson","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.clgc.2024.102217_bib0008","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.19.02712","article-title":"Adjuvant chemotherapy with etoposide plus cisplatin for patients with pathologic stage II nonseminomatous germ cell tumors","author":"McHugh","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.clgc.2024.102217_bib0009","doi-asserted-by":"crossref","first-page":"5597","DOI":"10.1200\/JCO.2007.12.0808","article-title":"Nonrandomized comparison of primary chemotherapy and retroperitoneal lymph node dissection for clinical stage IIA and IIB nonseminomatous germ cell testicular cancer","volume":"25","author":"Stephenson","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clgc.2024.102217_bib0010","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1016\/0959-8049(95)00330-L","article-title":"Clinical stage B non-seminomatous germ cell testis cancer: the Indiana University experience (1965-1989) using routine primary retroperitoneal lymph node dissection","volume":"31a","author":"Donohue","year":"1995","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.clgc.2024.102217_bib0011","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.euo.2023.06.004","article-title":"Retroperitoneal lymph node dissection in clinical stage IIA\/B metastatic seminoma: results of the COlogne trial of retroperitoneal lymphadenectomy in metastatic seminoma (COTRIMS)","volume":"7","author":"Heidenreich","year":"2024","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.clgc.2024.102217_bib0012","doi-asserted-by":"crossref","first-page":"3009","DOI":"10.1200\/JCO.22.00624","article-title":"Surgery in early metastatic seminoma: a phase II trial of retroperitoneal lymph node dissection for testicular seminoma with limited retroperitoneal lymphadenopathy","volume":"41","author":"Daneshmand","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clgc.2024.102217_bib0013","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.eururo.2022.10.021","article-title":"Phase 2 single-arm trial of primary retroperitoneal lymph node dissection in patients with seminomatous testicular germ cell tumors with clinical stage IIA\/B (PRIMETEST)","volume":"84","author":"Hiester","year":"2023","journal-title":"Eur Urol"},{"key":"10.1016\/j.clgc.2024.102217_bib0014","doi-asserted-by":"crossref","first-page":"2966","DOI":"10.1200\/JCO.2007.12.0899","volume":"26","author":"Albers","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.clgc.2024.102217_bib0015","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1200\/JCO.2008.18.8953","article-title":"Risk-adapted treatment in clinical stage I nonseminomatous germ cell testicular cancer: the SWENOTECA management program","volume":"27","author":"Tandstad","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clgc.2024.102217_bib0016","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1016\/j.eururo.2010.12.010","article-title":"Non-risk-adapted surveillance in clinical stage I nonseminomatous germ cell tumors: the Princess Margaret Hospital's experience","volume":"59","author":"Sturgeon","year":"2011","journal-title":"Eur Urol"},{"key":"10.1016\/j.clgc.2024.102217_bib0017","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1159\/000020197","article-title":"RPLND or primary chemotherapy in clinical stage IIA\/B nonseminomatous germ cell tumors? Results of a prospective multicenter trial including quality of life assessment","volume":"37","author":"Weissbach","year":"2000","journal-title":"Eur Urol"},{"key":"10.1016\/j.clgc.2024.102217_bib0018","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1097\/JU.0000000000000792","article-title":"Long-term oncologic outcomes after primary retroperitoneal lymph node dissection: minimizing the need for adjuvant chemotherapy","volume":"204","author":"Douglawi","year":"2020","journal-title":"J Urol"},{"key":"10.1016\/j.clgc.2024.102217_bib0019","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1200\/JCO.18.01480","article-title":"Serum levels of MicroRNA-371a-3p (M371 Test) as a new biomarker of testicular germ cell tumors: results of a prospective multicentric study","volume":"37","author":"Dieckmann","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clgc.2024.102217_bib0020","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.eururo.2019.10.005","article-title":"Serum MicroRNA-371a-3p levels predict viable germ cell tumor in chemotherapy-na\u00efve patients undergoing retroperitoneal lymph node dissection","volume":"77","author":"Lafin","year":"2020","journal-title":"Eur Urol"},{"key":"10.1016\/j.clgc.2024.102217_bib0021","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.euo.2023.10.021","article-title":"Evaluation of a miRNA-371a-3p assay for predicting final histopathology in patients undergoing primary nerve-sparing retroperitoneal lymphadenectomy for stage IIA\/B seminoma or nonseminoma","volume":"7","author":"Seelemeyer","year":"2024","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.clgc.2024.102217_bib0022","doi-asserted-by":"crossref","first-page":"3947","DOI":"10.1002\/cncr.32427","article-title":"Site of extranodal metastasis impacts survival in patients with testicular germ cell tumors","volume":"125","author":"Patel","year":"2019","journal-title":"Cancer"},{"key":"10.1016\/j.clgc.2024.102217_bib0023","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1016\/S0022-5347(05)67528-3","article-title":"Risk of systemic metastases in clinical stage I nonseminoma germ cell testis tumor managed by retroperitoneal lymph node dissection","volume":"163","author":"Hermans","year":"2000","journal-title":"J Urol"},{"key":"10.1016\/j.clgc.2024.102217_bib0024","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1016\/S0022-5347(17)52664-6","article-title":"Inguinal node metastases from testicular tumors in patients with prior orchiopexy","volume":"129","author":"Wheeler","year":"1983","journal-title":"J Urol"},{"key":"10.1016\/j.clgc.2024.102217_bib0025","doi-asserted-by":"crossref","first-page":"e391","DOI":"10.1016\/j.juro.2011.02.981","article-title":"970 pelvic metastases among patients undergoing retroperitoneal lymph node dissection for testicular cancer","volume":"185","author":"Mehan","year":"2011","journal-title":"J Urol"},{"key":"10.1016\/j.clgc.2024.102217_bib0026","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.urology.2016.08.063","article-title":"Management of pelvic metastases in patients with testicular cancer","volume":"102","author":"Jacob","year":"2017","journal-title":"Urology"},{"key":"10.1016\/j.clgc.2024.102217_bib0027","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/S0022-5347(01)66452-8","article-title":"Psychosocial aspects in long-term survivors of testicular cancer","volume":"155","author":"Arai","year":"1996","journal-title":"J Urol"},{"key":"10.1016\/j.clgc.2024.102217_bib0028","first-page":"645","article-title":"Health-related quality of life and psychosocial implications in testicular cancer survivors. A literature review","volume":"22","author":"Cappuccio","year":"2018","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"10.1016\/j.clgc.2024.102217_bib0029","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.urolonc.2005.03.004","article-title":"Quality of life in survivors of testicular cancer","volume":"23","author":"Dahl","year":"2005","journal-title":"Urol Oncol"},{"key":"10.1016\/j.clgc.2024.102217_bib0030","first-page":"145","article-title":"Clinical stage I nonseminoma: surgery versus surveillance","volume":"25","author":"Foster","year":"1998","journal-title":"Semin Oncol"},{"key":"10.1016\/j.clgc.2024.102217_bib0031","doi-asserted-by":"crossref","first-page":"2468","DOI":"10.1200\/JCO.21.01199","article-title":"Imaging modality and frequency in surveillance of stage I seminoma testicular cancer: results from a randomized, phase III, noninferiority trial (TRISST)","volume":"40","author":"Joffe","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clgc.2024.102217_bib0032","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/S0140-6736(04)15433-0","article-title":"Risk of cancer from diagnostic X-rays: estimates for the UK and 14 other countries","volume":"363","author":"Berrington de Gonz\u00e1lez","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.clgc.2024.102217_bib0033","doi-asserted-by":"crossref","first-page":"3111","DOI":"10.1038\/s41591-023-02620-0","article-title":"Risk of hematological malignancies from CT radiation exposure in children, adolescents and young adults","volume":"29","author":"Bosch de Basea Gomez","year":"2023","journal-title":"Nat Med"},{"key":"10.1016\/j.clgc.2024.102217_bib0034","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1097\/JU.0000000000002369","article-title":"Association of lymph node count and survival after primary retroperitoneal lymphadenectomy for nonseminomatous testicular cancer","volume":"207","author":"Patel","year":"2022","journal-title":"J Urol"},{"key":"10.1016\/j.clgc.2024.102217_bib0035","doi-asserted-by":"crossref","first-page":"5243","DOI":"10.1002\/cncr.25266","article-title":"Evaluation of lymph node counts in primary retroperitoneal lymph node dissection","volume":"116","author":"Thompson","year":"2010","journal-title":"Cancer"}],"container-title":["Clinical Genitourinary Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767324001873?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767324001873?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,5]],"date-time":"2025-05-05T16:44:14Z","timestamp":1746463454000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1558767324001873"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":35,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["S1558767324001873"],"URL":"https:\/\/doi.org\/10.1016\/j.clgc.2024.102217","relation":{},"ISSN":["1558-7673"],"issn-type":[{"value":"1558-7673","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Long-term Clinical Outcomes of Patients With Negative Pathology (pN0) at Primary Retroperitoneal Lymph Node Dissection","name":"articletitle","label":"Article Title"},{"value":"Clinical Genitourinary Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clgc.2024.102217","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"102217"}}